These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33309308)

  • 1. Integrated Bioinformatics Analysis for the Screening of Associated Pathways and Therapeutic Drugs in Coronavirus Disease 2019.
    Wang T; Zhao M; Ye P; Wang Q; Zhao Y
    Arch Med Res; 2021 Apr; 52(3):304-310. PubMed ID: 33309308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis.
    Tan S; Chen W; Xiang H; Kong G; Zou L; Wei L
    Genes Genomics; 2021 Jan; 43(1):55-67. PubMed ID: 33428154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the co-adaptation of codon usage between respiratory coronaviruses and their human host uncovers candidate therapeutics for COVID-19.
    Nambou K; Anakpa M
    Infect Genet Evol; 2020 Nov; 85():104471. PubMed ID: 32707288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
    Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
    PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analyses of bioinformatics applications in the fight against COVID-19 pandemic.
    Ma L; Li H; Lan J; Hao X; Liu H; Wang X; Huang Y
    Comput Biol Chem; 2021 Dec; 95():107599. PubMed ID: 34773807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.
    Zhu H; Chen CZ; Sakamuru S; Zhao J; Ngan DK; Simeonov A; Hall MD; Xia M; Zheng W; Huang R
    Sci Rep; 2021 Mar; 11(1):6725. PubMed ID: 33762619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
    Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
    J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
    Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
    Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
    Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated method for optimized identification of effective natural inhibitors against SARS-CoV-2 3CLpro.
    Liao Q; Chen Z; Tao Y; Zhang B; Wu X; Yang L; Wang Q; Wang Z
    Sci Rep; 2021 Nov; 11(1):22796. PubMed ID: 34815498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances of therapeutic targets and potential drugs of COVID-19.
    Zhang W; Zhang P; Wang G; Cheng W; Chen J; Zhang X
    Pharmazie; 2020 May; 75(5):161-163. PubMed ID: 32393419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

  • 16. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    J Virol; 2021 Aug; 95(18):e0068721. PubMed ID: 34191580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2.
    Ahsan MA; Liu Y; Feng C; Zhou Y; Ma G; Bai Y; Chen M
    Brief Bioinform; 2021 Mar; 22(2):714-725. PubMed ID: 33432321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus.
    Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34647577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.